Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.

The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. Keeping that in mind, here is one growth stock expanding its competitive advantage and two climbing an uphill battle.

Two Growth Stocks to Sell:

SoundHound AI (SOUN)

One-Year Revenue Growth: +101%

Founded in 2005, SoundHound AI (NASDAQ: SOUN) develops independent voice artificial intelligence solutions that enable businesses across various industries to offer customized conversational experiences to consumers.

Why Is SOUN Not Exciting?

1. Sky-high servicing costs result in an inferior gross margin of 44.1% that must be offset through increased usage
2. Operating margin fell by 39 percentage points over the last year as it prioritized growth over profits
3. Cash-burning tendencies make us wonder if it can sustainably generate shareholder value

At $9.55 per share, SoundHound AI trades at 25.4x forward price-to-sales. If you’re considering SOUN for your portfolio, see our FREE research report to learn more.

Corcept (CORT)

One-Year Revenue Growth: +30.9%

Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.

Why Are We Hesitant About CORT?

1. Revenue base of $685.4 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
2. Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 16.2 percentage points
3. 16.1 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position

Corcept is trading at $78.01 per share, or 39x forward P/E. To fully understand why you should be careful with CORT, check out our full research report (it’s free).

One Growth Stock to Watch:

Option Care Health (OPCH)

One-Year Revenue Growth: +17%

With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ: OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.

Why Do We Like OPCH?

1. Annual revenue growth of 15.3% over the last five years beat the sector average and underscores the unique value of its offerings
2. Share buybacks catapulted its annual earnings per share growth to 66.4%, which outperformed its revenue gains over the last five years
3. Free cash flow margin jumped by 3.3 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends

Option Care Health’s stock price of $31.41 implies a valuation ratio of 19x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

Stocks We Like Even More

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.